State of the market
On average over half the cost of developing a new cancer drug is associated with work outsourced to contract research organisations (CRO), according to analysis by Cutting Edge Information. This finding, coupled with the pharmaceutical industry’s ever present desire for more efficient R&D spending, means that finding the right contractor and monitoring performance is more important than ever.
In his presentation Eric Bolesh will examine this issue and discuss the following: How pharmaceutical firms work successfully with CROs? What clinical work is contracted out to third parties? How is vendor performance measured?; and how, ultimately, is this information used to shape future sourcing strategies and drug development projects be that for a new treatment for cancer or for any other disease.
Eric Bolesh, Gareth Macdonald
Cutting Edge Information
Eric Bolesh leads CEI's research division, and he has conducted studies on a range of different topics, including clinical development, brand commercialization and launch, patient communications, and business development and licensing. He is a regular speaker and author whose work has appeared in a range of media, including pharmaceutical publications such as Pharmaceutical Executive and MedAdNews as well as broader publications such as The Wall Street Journal and The New York Times.
Gareth covers news in the contract research services sector and edits the leading B2B news website Outsourcing-Pharma.com. He has an MSc in Bioinformatics from Exeter University and a BSc in Microbiology and Virology from the University of Warwick. Gareth has worked as a journalist for six years, reporting on topics ranging from drug discovery and manufacturing to pharmaceutical business development and finance.